NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:							
Provisional matrix of consultees and commentators sent for consultation							
Summary of comments, action taken, and justification of action:							
	Proposal:	Proposal made by:		Action taken: Removed/Added/Not included/Noted	Justification:		

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Rituximab for first line and relapsed chronic lymphocytic leukaemia

Issue date: August 2008

1.	Please ensure that the UK CLL	Chronic Lymphocytic Leukaemia	To be discussed at meeting	
	Forum medics are included in	Support Association		
	this scoping exercise. They are			
	the UK's experts on CLL, and			
	their ommision will invalidate the			
	exercise.			

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Rituximab for first line and relapsed chronic lymphocytic leukaemia

Issue date: August 2008

The British Committee for	Roche Products Ltd		To be discussed at meeting	
Standards in Haematology,				
United Kingdom CLL Forum and				
the National Cancer Research				
Network Lymphoma Clinical				
Studies Group may represent				
important stakeholders not				
currently included in the matrix				
of consultees and				
commentators.				
	Standards in Haematology, United Kingdom CLL Forum and the National Cancer Research Network Lymphoma Clinical Studies Group may represent important stakeholders not currently included in the matrix of consultees and	Standards in Haematology, United Kingdom CLL Forum and the National Cancer Research Network Lymphoma Clinical Studies Group may represent important stakeholders not currently included in the matrix of consultees and	Standards in Haematology, United Kingdom CLL Forum and the National Cancer Research Network Lymphoma Clinical Studies Group may represent important stakeholders not currently included in the matrix of consultees and	Standards in Haematology, United Kingdom CLL Forum and the National Cancer Research Network Lymphoma Clinical Studies Group may represent important stakeholders not currently included in the matrix of consultees and

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Rituximab for first line and relapsed chronic lymphocytic leukaemia

Issue date: August 2008